Result of AGM

RNS Number : 3678Q

Celadon Pharmaceuticals PLC

27 June 2022

 

Celadon Pharmaceuticals Plc

("Celadon" or the "Company") 

  Result of Annual General Meeting

London, UK, 27 June 2022 : Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development and supply of natural, cannabis-based medicines, announces that at its Annual General Meeting held today, all resolutions were duly passed.

Full details of the poll results will shortly be set out on the Company's website , along with Celadon's recent Business Update, which was published on 22 June 2022 .

Enquiries:

Celadon Pharmaceuticals Plc
James Short Arthur Wakeley	Via Powerscourt
Canaccord Genuity Limited (Nominated Adviser and Broker)
Andrew Potts / Patrick Dolaghan	[phone]
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil	[phone] [e-mail]

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and supply of natural cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence for the legal cultivation of high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns an MHRA conditionally approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.

For further information please visit our website www.celadonpharma.com

 

END

 

 

RAGBKOBKOBKDCAB